dc.contributor
Institut Català de la Salut
dc.contributor
[Cortes J] IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Twelves C] Leeds Institute of Medical Research at St James's, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Cortés Castan, Javier
dc.contributor.author
Twelves, Chris
dc.date.accessioned
2025-10-25T05:39:25Z
dc.date.available
2025-10-25T05:39:25Z
dc.date.issued
2021-10-22T06:44:47Z
dc.date.issued
2021-10-22T06:44:47Z
dc.identifier
Cortes J, Twelves C. Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis. Breast J. 2020 Jul;26(7):1347–51.
dc.identifier
https://hdl.handle.net/11351/6441
dc.identifier
10.1111/tbj.13686
dc.identifier
000499279600001
dc.identifier.uri
http://hdl.handle.net/11351/6441
dc.description.abstract
Càncer de mama avançat; Eribulina; Supervivència global
dc.description.abstract
Cáncer de mama avanzado; Eribulina; Supervivencia global
dc.description.abstract
Advanced breast cancer; Eribulin; Overall survival
dc.description.abstract
In a pivotal phase 3 study (Study 305), eribulin mesylate improved overall survival (OS) in patients with previously treated metastatic breast cancer (MBC) compared with treatment of physician's choice (TPC). This post hoc, pooled subgroup analysis of two phase 3 studies (Study 305 and Study 301) reports the influence of the number of prior chemotherapy regimens (0-6) on OS in patients with locally advanced/MBC randomized to eribulin versus TPC/capecitabine. Patients with ≤ 3 prior chemotherapies for locally advanced/MBC had longer median OS with eribulin (15.3 months) versus control (13.2 months; hazard ratio, 0.858; P = .01).
dc.description.abstract
This support was funded by Eisai Inc, Woodcliff Lake, NJ, USA.
dc.format
application/pdf
dc.relation
Breast Journal;26(7)
dc.relation
https://doi.org/10.1111/tbj.13686
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Quimioteràpia
dc.subject
Mama - Càncer - Prognosi
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome::Disease-Free Survival
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento::supervivencia sin enfermedad
dc.title
Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: a post hoc pooled analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
